AU9742298A

AU9742298A - Parasiticidal formulations

Info

Publication number: AU9742298A
Application number: AU97422/98A
Authority: AU
Inventors: Hiep Huatan
Original assignee: Pfizer Corp Belgium; Pfizer Inc
Current assignee: Pfizer Corp SRL
Priority date: 1997-09-23
Filing date: 1998-09-04
Publication date: 1999-04-12
Also published as: CA2304283A1; PE117199A1; PA8459501A1; WO1999015166A1; TNSN98175A1; GT199800149A; BR9812385A; AR013509A1; EP1014970A1; AP9801350A0; JP2001517622A; MA24655A1

Description

WO 99/15166 PCT/EP98/05720 Parasiticidal formulations This invention relates to a solid implant containing a parasiticidal compound having low aqueous solubility, which is particularly useful for administration to livestock such as 5 cattle, pigs and sheep. A number of potent macrocyclic parasiticidal compounds are known, including the avermectins and milbemycins. UK Patent No 1,573,955 discloses a family of avermectin compounds (including avermectins B 1 a and B 1 b) which are indicated as parasiticides. 10 22,23-Dihydroavermectin B 1 (ivermectin, disclosed in EP 1689) is available commercially in an injectable formulation (sold as IVOMECTM). Ivermectin is a mixture of at least 80% 22,23-dihydroavermectin Bla (having a 25-sec butyl group) and not more than 20% of 22,23-dihydroavermectin B 1 b (having a 25-isopropyl group). 15 25-Cyclohexyl-avermectin B1 (doramectin, disclosed in EP 214731) has the following structure,

OCH

3 HO OCH, 0"" H / C H HzC OH O,.. O HH HHH 0 C0" OH : OH H CH 3 OH and is available commercially in an oil formulation for injection (sold as DECTOMAX T M ) 20 for the treatment and prevention of internal and external parasite infestations in cattle. The oil formulation is described in European Patent N o 393890.

WO 99/15166 2 PCT/EP98/05720 The milbemycins are similar in structure to the avermectins, except that they are unsubstituted at the 13-position. Although formulations such as DECTOMAXTM have been successful, there is a need for 5 further formulations which are convenient to administer and which provide prolonged protection against parasites. European Patent Application 240274 discloses the use of avermectins as growth promoting agents. European Patent Application 311195 discloses the use of avermectins in the 10 prevention of fescue toxicosis in grazing animals. In both documents, a subcutaneous implant is claimed, but no teaching is provided about how such an implant would be produced. European Patent Application 473223 discloses a complex bioerodible implant in which 15 active agents such as anthelmintics are incorporated covalently into a chain backbone of a constituent polymer. European Patent Application 537998 discloses a drug delivery device compounded of a polymeric matrix, a vehicle (which is a plasticizing solvent for the polymeric matrix) and a 20 drug. The drug may be an avermectin or a milbemycin, and the device is intended for topical delivery of drugs, such as a flea or tick collar for pets. Thus, according to the present invention, there is provided a solid implant comprising at least one parasiticidal compound having low aqueous solubility; and tabletting excipients 25 including a bulking agent. An important feature of the implants of the present invention is their simplicity. Preferably therefore, greater than 95% by weight of the implant is made up of parasiticidal compound and tabletting excipients, more preferably greater than 99% by weight. 30 WO 99/15166 3 PCTIEP98/05720 Implants according to the invention may be implanted intramuscularly. Preferably however, they are implanted subcutaneously (i.e. into the fatty tissue directly below the skin). 5 Suitable parasiticidal compounds are those having an aqueous solubility below 100 gg/ml, for example the avermectins and milbemycins. Doramectin is of particular interest (which has an aqueous solubility of 0.6 ig/ml at pH 7). Ivermectin is also of interest. Preferably, the bulking agent is lactose. Other suitable bulking agents include other sugars, 10 microcrystalline cellulose (which is available commercially as AVICEL T M ) and dicalcium phosphate. Other tabletting excipients which may be present include magnesium stearate, which acts as a lubricant to facilitate tabletting. Typically, magnesium stearate will make up about 15 3% of the implant, by weight. Binding agents may also be included in the formulation to aid granulation and compressibility. Examples of binding agents include starch, gelatin and polyvinyl pyrrolidone. Typically, the binding agent, when present, will make up between 2 to 10% of the implant, by weight. 20 A further tabletting excipient which the implants of the invention may optionally contain is a tablet disintegrant. Suitable tablet disintegrants include sodium starch glycolate, which is available commercially as EXPLOTABTM. Other disintegrants which may be mentioned are dicalcium phosphate and cross-linked starch. Typically, the disintegrant, when present, will make up about 5% of the implant, by weight. 25 Preferably, the parasiticidal compound (or compounds) makes up between 10 and 60% of the implant, by weight, more preferably from 20 to 45% of the implant, by weight, for example 40%. 30 Preferably, the implants of the invention contain an antioxidant or a reducing agent. It has been found that such additives reduce or eliminate degradation of the parasiticidal compound, thus extending the shelf-life of the implant. It has been found that such WO 99/15166 4 PCT/EP98/05720 additives are particularly useful for stabilizing the parasiticidal compound when the implant is sterilized by irradiation, such as gamma or beta irradiation. Antioxidants of particular interest are butylated hydroxy anisole (BHA; a mixture of 2-tert 5 butyl-4-methoxyphenol and 3-tert-butyl-4-methoxyphenol) and butylated hydroxy toluene (BHT; 2,6-di-tert-butyl-4-methylphenol). Other antioxidants and reducing agents include alpha-tocopherol, alkyl gallate derivatives, nordihydroguaiaretic acid, ascorbic acid, sodium metabisulphate and sodium sulphite. Typically, the antioxidant, when present, will make up between 0.01 to 0.5% of the implant, by weight, more preferably 0.1 to 0.2%. 10 As mentioned above, the implants of the invention may be irradiated to sterilize them, typically at a dose in the range 15-25 kGy (kilo Gray). The implants of the invention may be implanted in various parts of the animal to be treated, 15 for example the flank, the base of the tail or the ear. Where the ears are removed during a meat rendering process, this is a preferred site for implantation. To facilitate such implantation, the implants are preferably rod-shaped, and can be implanted conveniently using a conventional hand-operated implant gun. Suitably, rod 20 shaped implants are 2 to 30 mm in length, and 2 to 5 mm in diameter. Preferred dimensions are 5 to 6 mm in length, and 2 to 3 mm in diameter. Preferably, the cross section is circular. According to the invention, there is also provided a method for the treatment or prevention 25 of parasitic infections which comprises administering an implant as defined above to an animal in need of such treatment. Parasitic infections of particular interest are those caused by endoparasites including helminthiasis (most frequently caused by nematode worms in the gastrointestinal tract). 30 The implants are also useful in treatment or prevention of ectoparasite infections such as of ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae.

WO 99/15166 5 PCTIEP98/05720 The dosage to be administered will depend on the animal to be treated, the parasiticidal compound being used, and the condition to be treated. However, a suitable dose of doramectin is 0.5 mg/kg of animal body weight. Typically, an implant according to the invention having the preferred dimensions mentioned above will contain about 10 mg of 5 doramectin. Thus, for cattle weighing 120 kg, 6 implants will be needed. This could provide sustained release of doramectin for up to 120 days. Where multiple implants are required, these can often be implanted consecutively by a single actuation of an implant gun. 10 Because implants according to the present invention can provide sustained release in cattle over an entire grazing season, administration need only take place once a year. Therefore, the invention provides the use of an avermectin or a milbemycin compound in the manufacture of an implant for treatment or prevention of parasitic infections, characterized in that the medicament is administered once a year. 15 The implants of the invention may be prepared by dry- or wet-mass granulation followed by milling and compression into the desired shape using conventional techniques. For example, an implant consisting of doramectin, lactose and magnesium stearate could 20 be prepared by dry-mass granulation using the following steps: 1. Blend components except magnesium stearate 2. Sieve through a screen 3. Blend 25 4. Add half of magnesium stearate 5. Blend 6. Compress into slugs 7. Mill slugs to granules 8. Collect desired size fraction of granules 30 9. Blend 10. Add remaining magnesium stearate 11. Blend WO 99/15166 6 PCT/EP98/05720 12. Compress into rods The steps for wet-mass granulation are similar, except that some components are sprayed onto other components while they are blending, in a solvent which is later removed. In 5 addition, a binder is used to aid the adherence of the individual particles. For example, in the preparation of an implant containing BHA and the binder PVP, BHA and PVP can be added to a blending mixture of components by spraying as a solution in ethanol. Thus, an implant consisting of doramectin, lactose, sodium starch glycolate, BHA, PVP and magnesium stearate could be prepared by wet-mass granulation using the following steps: 10 1. Blend components except magnesium stearate, BHA and PVP 2. Sieve through a screen 3. Blend 4. Spray solution of BHA and PVP in ethanol onto mixture while mixing 15 5. Sieve wet mass 6. Dry to granules 7. Mill 8. Collect desired size fraction 9. Blend 20 10. Add magnesium stearate 11. Blend 12. Compress into rods Thus, according to a further aspect of the invention, there is provided a process for the 25 production of an implant as defined above, which comprises mixing the parasiticidal compound with the tabletting excipients and forming into the desired shape. The duration of action of the implants of the invention may be determined by measuring blood plasma levels in cattle following implantation. These levels have been correlated 30 with antiparasitic activity of the compounds which have established that for effective control of helminths a blood plasma level of about 2 ng/ml needs to be maintained, and that WO 99/15166 7 PCT/EP98/05720 for effective control of single-host ticks a blood plasma level of about 5 ng/ml needs to be maintained. In a broader aspect, the invention further provides use of an antioxidant or a reducing agent 5 in a composition containing an avermectin or a milbemycin for preventing degradation of the avermectin or milbemycin. Although BHA has been used previously in association with doramectin in DECTOMAXTM, its function was to prevent rancidity of the oil formulation rather than to aid the stability of doramectin in solution. This aspect of the invention is particularly useful when the formulation is irradiated, and may be used in 10 liquid and non-liquid formulations (such as solids and powders). The invention is illustrated by the following examples, and the accompanying figures in which: Figure 1 shows the blood plasma levels in cattle achieved by the implants prepared in 15 Examples 1 and 2; and Figure 2 shows the degradation profiles of implants prepared in Example 4. Example 1 Doramectin implant 20 Components Specification mg/unit % by weight Doramectina Pfizer 10.000 40 3-anhydrous lactose Ph Eur 14.250 57 Magnesium stearate Ph Eur 0.750 3 Total 25.000 100 a mean particle size 19.27 jtm (volume mean diameter) The components, except magnesium stearate, were blended together in a blender for 15 25 minutes. The blend was then sieved through a 680 jtm mesh screen and blended for a further 15 minutes. After that, half of the magnesium stearate was added and blending WO 99/15166 8 PCT/EP98/05720 continued for 5 minutes, after which the blend was compressed to form "slugs". The slugs were then milled to form granules, and the size fraction 250-355 pim was collected. The collected granules were then blended for 15 minutes, and then the remaining half of 5 the magnesium stearate was added and blending continued for 5 minutes. The blend was then compressed on a suitable tablet machine using 2 mm tooling to produce rod-shaped implants of 2 mm diameter and 5 mm length. Example 2 10 Doramectin implant containing a tablet disintegrant Components Specification mg/unit % by weight Doramectina Pfizer 10.000 40 13-anhydrous lactose Ph Eur 13.000 52 Sodium starch BP 1.250 5 glycolate (XPLOTAB" h Magnesium stearate Ph Eur 0.750 3 Total 25.000 100 a mean particle size 19.27 pm (volume mean diameter) 15 The implants were prepared by the method of Example 1. Example 3 Pharmacokinetic profiling 20 The implants of Examples 1 and 2 were implanted into 16 cows at a dose of 500pg/kg. The blood plasma concentrations of doramectin following implantation were measured, and the results are shown in Figure 1. It can be seen that in each case single-host tick activity was obtained for more than 50 days, and control of helminths was obtained for about 90 days. 25 WO 99/15166 9 PCT/EP98/05720 Example 4 Doramectin implant containing an antioxidant Components Specification mg/unit % by weight Doramectina Pfizer 10.000 40 3-anhydrous lactose Ph Eur 11.625 46.5 Sodium starch glycolate BP 1.250 5

(EXPLOTAB

T m ) Butylated hydroxy anisole Ph Eur 0.125 0.5 Polyvinyl pyrrolidone Ph Eur 1.250 5 Magnesium stearate Ph Eur 0.750 3 Total 25.000 100 5 The components, except magnesium stearate, butylated hydroxy anisole and polyvinyl pyrrolidone, were blended together in a blender for 15 minutes. The blend was then sieved through a 680 pm mesh screen and blended for a further 15 minutes. After that, the butylated hydroxy anisole and polyvinyl pyrrolidone was dissolved in ethanol to form the granulation fluid. The volume of ethanol used was approximately 20%, by volume, of the 10 total formulation. The granulation fluid was sprayed onto the blend under constant mixing over 10 minutes. The resultant wet granule mass was sieved through a 1.4 mm mesh screen and allowed to dry under vacuum for 3 hours at 50 0 C. The dried granules were then milled, and the size fraction 250-355 pm was collected. 15 The collected granules were then blended for 15 minutes, and the magnesium stearate was added and blending continued for a further 5 minutes. The blend was then compressed on a suitable tabletting machine using a 2mm tooling to produce rod-shaped implants of 2mm diameter and 5 mm length. 20 These implants were used in stability studies, in which the effects of BHA and electron beam irradiation were investigated. Implants containing 0.5% w/w BHA and having been treated at four different irradiation levels [control (0 kGy), 15 kGy, 20 kGy and 25 kGy] WO 99/15166 10 PCT/EP98/05720 were stored at 30 0 C for 30 weeks, and then the percentage of doramectin remaining was determined. A control implant containing no BHA was also studied. The results are shown in Figure 2. It can be seen that the presence of BHA dramatically 5 improves the stability of the implants on storage, even when the implants have been irradiated.

Claims

1. A solid implant comprising at least one parasiticidal compound having low aqueous solubility; and tabletting excipients including a bulking agent. 5

2. An implant as claimed in claim 1, which is adapted for subcutaneous implantation.

3. An implant as claimed in claim 1 or claim 2, wherein the parasiticidal compound has an aqueous solubility below 100 tg/ml.

4. An implant as claimed in claim 3, wherein the parasiticidal compound is an avermectin or a milbemycin. 10

5. An implant as claimed in claim 4, wherein the parasiticidal compound is doramectin.

6. An implant as claimed in any one of the preceding claims, wherein the bulking agent is lactose.

7. An implant as claimed in any one of the preceding claims, wherein the tabletting 15 excipients include magnesium stearate.

8. An implant as claimed in any one of the preceding claims, wherein the tabletting excipients include a tablet disintegrant.

9. An implant as claimed in claim 8, wherein the tablet disintegrant is sodium starch glycolate. 20

10. An implant as claimed in any one of the preceding claims, which contains an antioxidant or a reducing agent.

11. An implant as claimed in claim 10, wherein the antioxidant is butylated hydroxy toluene or butylated hydroxy anisole.

12. An implant as claimed in any one of the preceding claims, which is suitable for 25 sterilization, or has been sterilized, by irradiation.

13. An implant as claimed in any one of the preceding claims, wherein the tabletting excipients include polyvinyl pyrrolidone.

14. An implant as claimed in any one of the preceding claims, wherein the parasiticidal compound makes up between 10 and 60% of the implant, by weight. 30

15. An implant as claimed in any one of the preceding claims, which is adapted for implantation into the ears of cattle or sheep.

16. An implant as claimed in any one of the preceding claims, which is rod-shaped. WO 99/15166 12 PCT/EP98/05720

17. Use of an antioxidant or a reducing agent in a formulation containing an avermectin or a milbemycin for preventing degradation of the avermectin or milbemycin.

18. The use as claimed in claim 17, wherein the formulation is suitable for sterilization, or has been sterilized, by irradiation. 5

19. The use as claimed in claim 17 or claim 18, wherein the formulation is not liquid.

20. A process for the production of an implant as defined in claim 1, which comprises mixing the parasiticidal compound with the tabletting excipients and forming into the desired shape.

21. A method for the treatment or prevention of parasitic infections which comprises 10 administering an implant as defined in any one of claims 1-16 to an animal in need of such treatment.